Athira Pharma Inc
For the period ended Dec 31, 2023. Filed Feb 22, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 22, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (included in signature pages hereto)
SIGNAT URES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Athira Pharma, Inc. | ||
| Date: February 22, 2024 | By: | /s/ Mark Litton |
|---|---|---|
| Mark Litton | ||
| President and Chief Executive Officer (Principal Executive Officer) | ||
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Mark Litton and Andrew Gengos, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with Exhibits thereto and other documents in connection therewith with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Mark Litton | President, Chief Executive Officer and Director | February 22, 2024 |
| Mark Litton | (Principal Executive Officer) | |
| /s/ Andrew Gengos | Chief Financial Officer and Chief Business Officer | February 22, 2024 |
| Andrew Gengos | (Principal Financial and Accounting Officer) | |
| /s/ Kelly A. Romano | Chairwoman of the Board of Directors | February 22, 2024 |
| Kelly A. Romano | ||
| /s/ Joseph Edelman | Director | February 22, 2024 |
| Joseph Edelman | ||
| /s/ John M. Fluke, Jr. | Director | February 22, 2024 |
| John M. Fluke, Jr. | ||
| /s/ James A. Johnson | Director | February 22, 2024 |
| James A. Johnson | ||
| /s/ Barbara Kosacz | Director | February 22, 2024 |
| Barbara Kosacz | ||
| /s/ Michael Panzara | Director | February 22, 2024 |
| Michael Panzara | ||
| /s/ Grant Pickering | Director | February 22, 2024 |
| Grant Pickering | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.